Donald C. McMillan

TL;DR: The complex interplay between local immune responses and systemic inflammation, and their influence on clinical outcomes, are examined, and potential anti-inflammatory interventions for patients with cancer are proposed.

TL;DR: The present systematic review examines and comments on the clinical utility of the neutrophil-lymphocyte ratio, which has shown that NLR is elevated in patients with more advanced or aggressive disease evidenced by increased tumour stage, nodal stage, number of metastatic lesions and as such these patients may represent a particularly high-risk patient population.

TL;DR: The GPS/mGPS is the most extensively validated of the systemic inflammation-based prognostic scores and therefore may be used in the routine clinical assessment of patients with cancer and provides a well defined therapeutic target for future clinical trials.

TL;DR: Good evidence is demonstrated that there is now good evidence that preoperative measures of the systemic inflammatory response predict cancer survival, independent of tumor stage, in primary operable cancer.

TL;DR: Systemic inflammation-based prognostic scores not only identify patients at risk but also provide well defined therapeutic targets for future clinical trials targeting nutritional decline.